vault backup: 2026-04-05 15:37:59
This commit is contained in:
Yanxin Lu
702
documents/medical/pacific/jiang_exams_2021.md
Normal file
702
documents/medical/pacific/jiang_exams_2021.md
Normal file
@@ -0,0 +1,702 @@
|
||||
---
|
||||
type: lab-results
|
||||
category: fertility-workup
|
||||
person: Jiang, Erica (Xuewei)
|
||||
date: 2021-09-15
|
||||
provider: Candice B. Tilles, MD
|
||||
source: jiang_exams_2021.pdf
|
||||
---
|
||||
|
||||
# Exams 2021 - Erica Jiang
|
||||
|
||||
**Patient:** Erica Jiang | **DOB:** 3/13/1993 | **MRN:** 20018501333 | **PCP:** Elizabeth Spence, DO
|
||||
|
||||
**Source:** MyChart - Test Details (mychartor.providence.org)
|
||||
|
||||
---
|
||||
|
||||
## Provider Message
|
||||
|
||||
**Candice B. Tilles, MD** - 09/24/2021, 12:58 PM
|
||||
|
||||
> Hi Erica,
|
||||
>
|
||||
> Your hormone levels were normal and your titers show that you are immune to measles, rubella and chicken pox. You have good ovarian reserve based on he Anti-mullerian Hormone level. The genetic carrier screening is still pending. Please contact me if you have any questions.
|
||||
>
|
||||
> Dr. Tilles
|
||||
|
||||
---
|
||||
|
||||
## ANTI-MULLERIAN HORMONE
|
||||
|
||||
**Collected on:** Sep 15, 2021 2:09 PM
|
||||
|
||||
| Test | Value | Unit | Reference Range |
|
||||
|------|-------|------|-----------------|
|
||||
| Antimullerian Hormone (AMH) | 2.50 | ng/mL | Females 26-30y: 1.03 - 11.10 (Median 4.20) |
|
||||
|
||||
**Performed at:** 01 - Esoterix Inc, 4301 Lost Hills Road, Calabasas Hills, CA 913015358
|
||||
**Lab Director:** Brian Poirier MD, Phone: 8004449111
|
||||
|
||||
For assays employing antibodies, the possibility exists for interference by heterophile antibodies in the samples.
|
||||
|
||||
1. Kricka L. Interferences in Immunoassays - still a threat. Clin. Chem. 2000; 46: 1037-1038.
|
||||
|
||||
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.
|
||||
|
||||
AMH concentrations of >= 1.06 ng/mL is correlated with a better response to ovarian stimulation, produced more retrievable oocytes and higher odds of live birth according to Gleicher et al. Fertility and Sterility. 2010: 94:2824-2827. The current AMH test method correlates with the study method with a slope of 0.94.
|
||||
|
||||
Females at risk of ovarian hyperstimulation syndrome or polycystic ovarian syndrome (PCOS) may exhibit elevated serum AMH concentrations. AMH levels from PCOS patients may be 2 to 5 fold higher than age-appropriate reference interval values.
|
||||
|
||||
Granulosa cell tumors of the ovary may secrete AMH along with other tumor markers. Elevated AMH is not specific for malignancy, and the assay should not be used exclusively to diagnose or exclude an AMH-secreting ovarian tumor.
|
||||
|
||||
**Ordering provider:** Candice B. Tilles, MD
|
||||
**Collection date:** Sep 15, 2021 2:09 PM
|
||||
**Specimens:** Blood (Arm, Left)
|
||||
**Result date:** Sep 18, 2021 5:05 PM
|
||||
**Result status:** Final
|
||||
**Resulting lab:** REFERENCE LAB LABCORP - BKR, 13112 Evening Creek Drive South, San Diego CA 92128, 858-668-3700
|
||||
**Lab director:** Jenny Galloway, MD
|
||||
|
||||
---
|
||||
|
||||
## CBC W/DIFFERENTIAL
|
||||
|
||||
**Collected on:** Sep 15, 2021 2:09 PM
|
||||
|
||||
**Performed at:** 01 - LabCorp San Diego, 13112 Evening Creek Dr So Ste 200, San Diego, CA 921284108
|
||||
**Lab Director:** Jenny Galloway MD, Phone: 8586683700
|
||||
|
||||
| Test | Value | Unit | Normal Range |
|
||||
|------|-------|------|--------------|
|
||||
| WBC | 4 | x10E3/uL | 3.4 - 10.8 |
|
||||
| Red Blood Cells | 4.31 | x10E6/uL | 3.77 - 5.28 |
|
||||
| Hemoglobin | 13.2 | g/dL | 11.1 - 15.9 |
|
||||
| Hct | 41.8 | % | 34.0 - 46.6 |
|
||||
| MCV | 97 | fL | 79 - 97 |
|
||||
| MCH | 30.6 | pg | 26.6 - 33.0 |
|
||||
| MCHC | 31.6 | g/dL | 31.5 - 35.7 |
|
||||
| RDW | 11.9 | % | 11.7 - 15.4 |
|
||||
| Platelet Count | 227 | x10E3/uL | 150 - 450 |
|
||||
| % Neutrophils | 38 | % | Not Estab. |
|
||||
| % Lymphocytes | 52 | % | Not Estab. |
|
||||
| % Monocytes | 8 | % | Not Estab. |
|
||||
| % Eosinophils | 1 | % | Not Estab. |
|
||||
| % Basophils | 1 | % | Not Estab. |
|
||||
| Absolute Neutrophils | 1.5 | x10E3/uL | 1.4 - 7.0 |
|
||||
| Absolute Lymphocytes | 2.1 | x10E3/uL | 0.7 - 3.1 |
|
||||
| Absolute Monocytes | 0.3 | x10E3/uL | 0.1 - 0.9 |
|
||||
| Absolute Eosinophils | 0 | x10E3/uL | 0.0 - 0.4 |
|
||||
| Absolute Basophils | 0 | x10E3/uL | 0.0 - 0.2 |
|
||||
| % Immature Granulocytes | 0 | % | Not Estab. |
|
||||
| Absolute Immature Granulocytes | 0 | x10E3/uL | 0.0 - 0.1 |
|
||||
|
||||
**Ordering provider:** Candice B. Tilles, MD
|
||||
**Collection date:** Sep 15, 2021 2:09 PM
|
||||
**Specimens:** Blood (Arm, Left)
|
||||
**Result date:** Sep 20, 2021 2:06 PM
|
||||
**Result status:** Final
|
||||
**Resulting lab:** REFERENCE LAB LABCORP - BKR, 13112 Evening Creek Drive South, San Diego CA 92128, 858-668-3700
|
||||
**Lab director:** Jenny Galloway, MD
|
||||
|
||||
---
|
||||
|
||||
## ESTRADIOL
|
||||
|
||||
**Collected on:** Sep 15, 2021 2:09 PM
|
||||
|
||||
| Test | Value | Unit | Reference Range |
|
||||
|------|-------|------|-----------------|
|
||||
| Estradiol | 48.2 | pg/mL | See Comment |
|
||||
|
||||
Estradiol Female Premenopausal Reference Range: 21.8-693.1 pg/mL
|
||||
Estradiol Female Postmenopausal Reference Range: 32.1-73.1 pg/mL
|
||||
|
||||
**Ordering provider:** Candice B. Tilles, MD
|
||||
**Collection date:** Sep 15, 2021 2:09 PM
|
||||
**Specimens:** Blood (Arm, Left)
|
||||
**Result date:** Sep 15, 2021 7:50 PM
|
||||
**Result status:** Final
|
||||
**Resulting lab:** CA PJNF WOMENS HEALTH SM LAB (CLIA 05D0550213), 2001 SANTA MONICA BLVD STE 970W, SANTA MONICA CA 90404-2199, 310-829-7878
|
||||
**Lab director:** Jon S. Matsunaga, MD
|
||||
**CLIA #:** 05D0550213
|
||||
|
||||
---
|
||||
|
||||
## Free T4
|
||||
|
||||
**Collected on:** Sep 15, 2021 2:09 PM
|
||||
|
||||
| Test | Value | Unit | Normal Range |
|
||||
|------|-------|------|--------------|
|
||||
| FT4 | 1.18 | ng/dL | 0.75 - 1.54 |
|
||||
|
||||
**Ordering provider:** Candice B. Tilles, MD
|
||||
**Collection date:** Sep 15, 2021 2:09 PM
|
||||
**Specimens:** Blood (Arm, Left)
|
||||
**Result date:** Sep 15, 2021 7:50 PM
|
||||
**Result status:** Final
|
||||
**Resulting lab:** CA PJNF WOMENS HEALTH SM LAB (CLIA 05D0550213), 2001 SANTA MONICA BLVD STE 970W, SANTA MONICA CA 90404-2199, 310-829-7878
|
||||
**Lab director:** Jon S. Matsunaga, MD
|
||||
**CLIA #:** 05D0550213
|
||||
|
||||
---
|
||||
|
||||
## FSH - FOLLICLE STIMULATING HORMONE
|
||||
|
||||
**Collected on:** Sep 15, 2021 2:09 PM
|
||||
|
||||
| Test | Value | Unit | Reference Range |
|
||||
|------|-------|------|-----------------|
|
||||
| Follicle Stimulating Hormone | 9.0 | mIU/mL | See Comment |
|
||||
|
||||
FSH Female premenopausal reference range: 2.7-23.0 mIU/mL
|
||||
FSH Female postmenopausal reference range: 25.0-160.0 mIU/mL
|
||||
|
||||
**Ordering provider:** Candice B. Tilles, MD
|
||||
**Collection date:** Sep 15, 2021 2:09 PM
|
||||
**Specimens:** Blood (Arm, Left)
|
||||
**Result date:** Sep 15, 2021 7:50 PM
|
||||
**Result status:** Final
|
||||
**Resulting lab:** CA PJNF WOMENS HEALTH SM LAB (CLIA 05D0550213), 2001 SANTA MONICA BLVD STE 970W, SANTA MONICA CA 90404-2199, 310-829-7878
|
||||
**Lab director:** Jon S. Matsunaga, MD
|
||||
**CLIA #:** 05D0550213
|
||||
|
||||
---
|
||||
|
||||
## Glyco Hgb
|
||||
|
||||
**Collected on:** Sep 15, 2021 2:09 PM
|
||||
|
||||
**Performed at:** 01 - LabCorp San Diego, 13112 Evening Creek Dr So Ste 200, San Diego, CA 921284108
|
||||
**Lab Director:** Jenny Galloway MD, Phone: 8586683700
|
||||
|
||||
| Test | Value | Unit | Normal Range |
|
||||
|------|-------|------|--------------|
|
||||
| Hemoglobin A1c | 5.3 | % | 4.8 - 5.6 |
|
||||
| Estimated Average Glucose | 105 | mg/dL | - |
|
||||
|
||||
Prediabetes: 5.7 - 6.4
|
||||
Diabetes: >6.4
|
||||
Glycemic control for adults with diabetes: <7.0
|
||||
|
||||
**Ordering provider:** Candice B. Tilles, MD
|
||||
**Collection date:** Sep 15, 2021 2:09 PM
|
||||
**Specimens:** Blood (Arm, Left)
|
||||
**Result date:** Sep 20, 2021 2:06 PM
|
||||
**Result status:** Final
|
||||
**Resulting lab:** REFERENCE LAB LABCORP - BKR, 13112 Evening Creek Drive South, San Diego CA 92128, 858-668-3700
|
||||
**Lab director:** Jenny Galloway, MD
|
||||
|
||||
---
|
||||
|
||||
## Misc Referral - Inheritest Comprehensive (Genetic Carrier Screening)
|
||||
|
||||
**Collected on:** Sep 15, 2021 2:09 PM
|
||||
|
||||
### Provider Message
|
||||
|
||||
**Candice B. Tilles, MD** - 10/1/2021, 1:06 PM
|
||||
|
||||
> Hi Erica,
|
||||
>
|
||||
> Your carrier screening was negative for all mutations tested. Please contact me if you have any questions.
|
||||
>
|
||||
> Dr. Tilles
|
||||
|
||||
### Test Information
|
||||
|
||||
**Performed At:** 01 Esoterix Genetic Laboratories, 3400 Computer Drive Westborough, MA 015811771, Zhu Hui PhD Ph:8002557357
|
||||
**Performed At:** 02 LabCorp San Diego, 13112 Evening Creek Dr So Ste 200 San Diego, CA 921284108, Galloway Jenny R MD Ph:8586683700
|
||||
|
||||
**Test Ordered:** 451950 Inheritest Comprehensive
|
||||
**Specimen Type:** InheriTest Comment 01 - Whole Blood
|
||||
**Ethnicity:** InheriTest Comment 01 - Not Provided
|
||||
**Indication:** Comment 01 - not provided
|
||||
|
||||
### Comprehensive Result
|
||||
|
||||
| Disorder (Gene) | Results | Interpretation |
|
||||
|-----------------|---------|----------------|
|
||||
| Spinal Muscular Atrophy (SMN1) | NEGATIVE | 2 copies of SMN1; negative for c.*3+80T>G SNP. This result reduces, but does not eliminate the risk to be a carrier. For ethnic-specific risk revisions see Information Table. |
|
||||
| Fragile X syndrome (FMR1) | PCR: 29 and 30 repeats | Negative: not a carrier of a fragile X expansion mutation. This result is not associated with fragile X syndrome. |
|
||||
| All other disorders | Negative for the mutations analyzed | These results reduce, but do not eliminate, the chance to be a carrier. See Information Tables. |
|
||||
|
||||
### SMA Risk Reductions (Individuals with No Family History)
|
||||
|
||||
**Reference Sequence:** Spinal Muscular Atrophy (SMN1) NM_000344
|
||||
|
||||
| Population | Detection Rate | Pre-test carrier risk | Post-test risk of being a carrier (Copy risk with 2 copies + SNP) | Post-test risk POSITIVE for c.*3+80T>G SNP | Post-test risk NEGATIVE with 3 copies for the c.*3+80T>G SNP |
|
||||
|------------|---------------|----------------------|-------|-------|-------|
|
||||
| African American | 90.3% | 1 in 72 | 1 in 34 | 1 in 375 | 1 in 4200 |
|
||||
| Asian | 93.6% | 1 in 59 | High risk | 1 in 907 | 1 in 5600 |
|
||||
| Caucasian | 95.0% | 1 in 47 | 1 in 29 | 1 in 921 | 1 in 5600 |
|
||||
| Hispanic | 92.6% | 1 in 68 | 1 in 140 | 1 in 906 | 1 in 5400 |
|
||||
|
||||
Mixed or Other ethnic background: For counseling purposes, consider using the most conservative Background risk estimates.
|
||||
|
||||
** includes carriers who are silent carriers (2+0) and Carriers with a pathogenic variant not detected in this Assay
|
||||
|
||||
References: Feng, PMID 28125085; Lou, PMID 23788250; Sugarman, PMID 21811307
|
||||
|
||||
### Gene-Specific Risk Reductions (Individuals with No Family History)
|
||||
|
||||
| Disorder (Gene) | Reference Sequence | Population | Detection Rate | Pre-Test Carrier Risk | Post-Test Carrier Risk with Negative Result |
|
||||
|-----------------|-------------------|------------|---------------|----------------------|---------------------------------------------|
|
||||
| Abetalipoproteinemia (MTTP) | NM_000253 | Ashkenazi Jewish | N/A* | N/A | N/A |
|
||||
| Adenosine deaminase deficiency (ADA) | NM_000022 | General | 42% | 1 in 289 | 1 in 497 |
|
||||
| Alpha-mannosidosis (MAN2B1) | NM_000528 | Caucasian | 63% | 1 in 350 | 1 in 944 |
|
||||
| Alpha-thalassemia (HBA1, HBA2) | 16p13.3 | African | 90% | 1 in 3 | N/A |
|
||||
| Alpha-thalassemia (HBA1, HBA2) | 16p13.3 | American | 90% | 1 in 21 | N/A |
|
||||
| Alpha-thalassemia (HBA1, HBA2) | 16p13.3 | Eastern Mediterranean | 90% | 1 in 5 | N/A |
|
||||
| Alpha-thalassemia (HBA1, HBA2) | 16p13.3 | European | 90% | 1 in 44 | N/A |
|
||||
| Alpha-thalassemia (HBA1, HBA2) | 16p13.3 | Southeast Asian | 90% | 1 in 2 | N/A |
|
||||
| Alpha-thalassemia (HBA1, HBA2) | 16p13.3 | Western Pacific | 90% | 1 in 10 | N/A |
|
||||
| Alport syndrome, COL4A3-related (COL4A3) | NM_000091 | Ashkenazi Jewish | 95% | 1 in 183 | 1 in 3640 |
|
||||
| Andermann syndrome (SLC12A6) | NM_133647 | French Canadian | 99% | 1 in 23 | 1 in 2200 |
|
||||
| Argininosuccinic aciduria (ASL) | NM_000048 | Finnish | 86% | 1 in 190 | 1 in 1350 |
|
||||
| Argininosuccinic aciduria (ASL) | NM_000048 | Worldwide | 59% | 1 in 132 | 1 in 320 |
|
||||
| Arthrogryposis, mental retardation, and seizures (AMRS) (SLC35A3) | NM_012243 | Ashkenazi Jewish | N/A* | N/A | N/A |
|
||||
| Aspartylglucosaminuria (AGA) | NM_000027 | Finnish | 98% | 1 in 81 | 1 in 4000 |
|
||||
| Ataxia with vitamin E deficiency (TTPA) | NM_000370 | Italian | 80% | N/A* | N/A |
|
||||
| Ataxia with vitamin E deficiency (TTPA) | NM_000370 | North African | 99% | N/A* | N/A |
|
||||
| Ataxia-telangiectasia (ATM) | NM_000051 | Amish | 99% | N/A* | N/A |
|
||||
| Ataxia-telangiectasia (ATM) | NM_000051 | Costa Rican | 56% | 1 in 100 | 1 in 226 |
|
||||
| Ataxia-telangiectasia (ATM) | NM_000051 | North African Jewish | 97% | 1 in 81 | 1 in 2667 |
|
||||
| Ataxia-telangiectasia (ATM) | NM_000051 | Norwegian | 55% | 1 in 197 | 1 in 436 |
|
||||
| Ataxia-telangiectasia (ATM) | NM_000051 | Worldwide | 40% | 1 in 100 | 1 in 166 |
|
||||
| Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) (SACS) | NM_014363 | French Canadian | 96% | 1 in 21 | 1 in 500 |
|
||||
| Bardet-Biedl syndrome, BBS1-related (BBS1) | NM_024649 | Worldwide | 55% | 1 in 390 | 1 in 865 |
|
||||
| Bardet-Biedl syndrome, BBS2-related (BBS2) | NM_031885 | Ashkenazi Jewish | N/A* | 1 in 136 | N/A |
|
||||
| Bardet-Biedl syndrome, BBS10-related (BBS10) | NM_024685 | Worldwide | 45% | 1 in 418 | 1 in 759 |
|
||||
| Beta hemoglobinopathy, beta thalassemias (HBB) | NM_000518 | African American | 90% | 1 in 50 | 1 in 741 |
|
||||
| Beta hemoglobinopathy, beta thalassemias (HBB) | NM_000518 | East Asian | 93% | 1 in 20 | 1 in 700 |
|
||||
| Beta hemoglobinopathy, beta thalassemias (HBB) | NM_000518 | Mediterranean | 97% | 1 in 20 | 1 in 634 |
|
||||
| Beta hemoglobinopathy, beta thalassemias (HBB) | NM_000518 | Middle Eastern | 84% | 1 in 30 | 1 in 182 |
|
||||
| Beta hemoglobinopathy, beta thalassemias (HBB) | NM_000518 | South Asian | 95% | 1 in 20 | 1 in 381 |
|
||||
| Beta hemoglobinopathy, beta thalassemias (HBB) | NM_000518 | Southeast Asian | 90% | 1 in 30 | 1 in 291 |
|
||||
| Beta hemoglobinopathy, hemoglobins C, D, E, and O (HBB) | NM_000518 | African American | >99% | 1 in 46 | Negligible |
|
||||
| Beta hemoglobinopathy, hemoglobins C, D, E, and O (HBB) | NM_000518 | Asian | >99% | 1 in 119 | Negligible |
|
||||
| Beta hemoglobinopathy, hemoglobins C, D, E, and O (HBB) | NM_000518 | Asian Indian | >99% | 1 in 68 | Negligible |
|
||||
| Beta hemoglobinopathy, hemoglobins C, D, E, and O (HBB) | NM_000518 | Middle Eastern | >99% | 1 in 255 | Negligible |
|
||||
| Beta hemoglobinopathy, hemoglobins C, D, E, and O (HBB) | NM_000518 | Native American | >99% | 1 in 292 | Negligible |
|
||||
| Beta hemoglobinopathy, hemoglobins C, D, E, and O (HBB) | NM_000518 | Southeast Asian | >99% | 1 in 15 | Negligible |
|
||||
| Beta hemoglobinopathy, sickle cell disease (HBB) | NM_000518 | African American | >99% | 1 in 14 | Negligible |
|
||||
| Beta hemoglobinopathy, sickle cell disease (HBB) | NM_000518 | Hispanic | >99% | 1 in 183 | Negligible |
|
||||
| Beta hemoglobinopathy, sickle cell disease (HBB) | NM_000518 | Middle Eastern | >99% | 1 in 360 | Negligible |
|
||||
| Beta hemoglobinopathy, sickle cell disease (HBB) | NM_000518 | Native American | >99% | 1 in 176 | Negligible |
|
||||
| Beta-mannosidosis (MANBA) | NM_005908 | Worldwide | 81% | N/A* | N/A |
|
||||
| Bloom syndrome (BLM) | NM_000057 | Ashkenazi Jewish | 97% | 1 in 134 | 1 in 4434 |
|
||||
| Canavan disease (ASPA) | NM_000049 | Ashkenazi Jewish | 98% | 1 in 55 | 1 in 2700 |
|
||||
| Carbamoyl phosphate synthetase I deficiency (CPS1) | NM_001875 | Worldwide | 48% | 1 in 570 | 1 in 1095 |
|
||||
| Carnitine palmitoyltransferase II deficiency (CPT2) | NM_000098 | Caucasian | 72% | N/A* | N/A |
|
||||
| Carnitine-acylcarnitine translocase deficiency (SLC25A20) | NM_000387 | Worldwide | N/A* | N/A | N/A |
|
||||
| Cartilage-hair hypoplasia (RMRP) | NM_003051 | Amish | 91% | 1 in 19 | 1 in 200 |
|
||||
| Cartilage-hair hypoplasia (RMRP) | NM_003051 | Finnish | 92% | 1 in 76 | 1 in 938 |
|
||||
| Cartilage-hair hypoplasia (RMRP) | NM_003051 | Worldwide | 48% | N/A* | N/A |
|
||||
| Citrullinemia type I (ASS1) | NM_000050 | Japanese | 71% | N/A* | N/A |
|
||||
| Citrullinemia type I (ASS1) | NM_000050 | Worldwide | 52% | 1 in 119 | 1 in 247 |
|
||||
| Cobalamin C disease (MMACHC) | NM_015506 | Worldwide | 89% | N/A* | N/A |
|
||||
| Cohen syndrome (VPS13B) | NM_017890 | Finnish | 75% | N/A* | N/A |
|
||||
| Cohen syndrome (VPS13B) | NM_017890 | Worldwide | 54% | N/A* | N/A |
|
||||
| Congenital amegakaryocytic thrombocytopenia (MPL) | NM_005373 | Ashkenazi Jewish | 95% | 1 in 75 | 1 in 1480 |
|
||||
| Congenital disorder of glycosylation type 1a (PMM2) | NM_000303 | Caucasian | 89% | 1 in 71 | 1 in 637 |
|
||||
| Cystic fibrosis (CFTR) | NM_000492 | African American | >81% | 1 in 61 | 1 in 316 |
|
||||
| Cystic fibrosis (CFTR) | NM_000492 | Ashkenazi Jewish | >97% | 1 in 24 | 1 in 767 |
|
||||
| Cystic fibrosis (CFTR) | NM_000492 | Asian American | >55% | 1 in 94 | 1 in 208 |
|
||||
| Cystic fibrosis (CFTR) | NM_000492 | Caucasian | >93% | 1 in 25 | 1 in 343 |
|
||||
| Cystic fibrosis (CFTR) | NM_000492 | Hispanic | >78% | 1 in 58 | 1 in 260 |
|
||||
| Cystinosis (CTNS) | NM_004937 | French Canadian | 70% | 1 in 39 | 1 in 127 |
|
||||
| Cystinosis (CTNS) | NM_004937 | Worldwide | 61% | 1 in 158 | 1 in 403 |
|
||||
| D-bifunctional protein deficiency (HSD17B4) | NM_000414 | Worldwide | 51% | N/A* | N/A |
|
||||
| Dihydrolipoamide dehydrogenase deficiency (DLD) | NM_000108 | Ashkenazi Jewish | 95% | 1 in 107 | 1 in 2121 |
|
||||
| Dihydropyrimidine dehydrogenase deficiency (DPYD) | NM_000110 | Northern European Caucasian | 71% | N/A* | N/A |
|
||||
| Dystrophinopathies, including Duchenne and Becker muscular dystrophies and cardiomyopathies (DMD) | NM_004006 | Worldwide | 95% | N/A** | N/A |
|
||||
| Ehlers-Danlos syndrome type VIIC (ADAMTS2) | NM_014244 | Ashkenazi Jewish | 95% | N/A* | N/A |
|
||||
| Ehlers-Danlos syndrome type VIIC (ADAMTS2) | NM_014244 | Worldwide | 80% | N/A* | N/A |
|
||||
| Ethylmalonic encephalopathy (ETHE1) | NM_014297 | Mediterranean/Arab | 61% | N/A* | N/A |
|
||||
| Familial dysautonomia (IKBKAP) | NM_003640 | Ashkenazi Jewish | 99% | 1 in 31 | 1 in 3000 |
|
||||
| Familial hyperinsulinism, ABCC8-related (ABCC8) | NM_000352 | Ashkenazi Jewish | 97% | 1 in 52 | 1 in 1700 |
|
||||
| Familial hyperinsulinism, ABCC8-related (ABCC8) | NM_000352 | Finnish | 43% | 1 in 101 | 1 in 175 |
|
||||
| Familial Mediterranean fever (MEFV) | NM_000243 | Arab | 71% | 1 in 5 | 1 in 14 |
|
||||
| Familial Mediterranean fever (MEFV) | NM_000243 | Armenian | 78% | 1 in 5 | 1 in 19 |
|
||||
| Familial Mediterranean fever (MEFV) | NM_000243 | Ashkenazi Jewish | 69% | 1 in 81**** | 1 in 259 |
|
||||
| Familial Mediterranean fever (MEFV) | NM_000243 | North African Jewish | 94% | 1 in 7 | 1 in 100 |
|
||||
| Familial Mediterranean fever (MEFV) | NM_000243 | Turkish | 74% | 1 in 5 | 1 in 16 |
|
||||
| Fanconi anemia group C (FANCC) | NM_000136 | Ashkenazi Jewish | 99% | 1 in 100 | 1 in 9900 |
|
||||
| Fucosidosis (FUCA1) | NM_000147 | Worldwide | 80% | N/A* | N/A |
|
||||
| Galactosemia, GALT-related (GALT) | NM_000155 | African American | 65% | 1 in 78 | 1 in 221 |
|
||||
| Galactosemia, GALT-related (GALT) | NM_000155 | Ashkenazi Jewish | 88% | 1 in 127 | 1 in 1050 |
|
||||
| Galactosemia, GALT-related (GALT) | NM_000155 | Caucasian | 81% | 1 in 108 | 1 in 564 |
|
||||
| Galactosialidosis (CTSA) | NM_000308 | Japanese | 60% | N/A* | N/A |
|
||||
| Gaucher disease (GBA) | NM_001005741 | Ashkenazi Jewish | 98% | 1 in 15 | 1 in 700 |
|
||||
| Glutaric acidemia type 1 (GCDH) | NM_000159 | Amish | 94% | 1 in 9 | 1 in 134 |
|
||||
| Glutaric acidemia type 1 (GCDH) | NM_000159 | German | 55% | 1 in 158 | 1 in 350 |
|
||||
| Glutathione synthetase deficiency (GSS) | NM_000178 | Worldwide | 67% | N/A* | N/A |
|
||||
| Glycine encephalopathy, AMT-related (AMT) | NM_000481 | Worldwide | 50% | N/A* | N/A |
|
||||
| Glycine encephalopathy, GLDC-related (GLDC) | NM_000170 | Finnish | 70% | 1 in 117 | 1 in 387 |
|
||||
| Glycogen storage disease type Ia (G6PC) | NM_000151 | Ashkenazi Jewish | 99% | 1 in 64 | 1 in 6300 |
|
||||
| Glycogen storage disease type Ia (G6PC) | NM_000151 | Worldwide | 81% | 1 in 177 | 1 in 927 |
|
||||
| Glycogen storage disease type Ib (SLC37A4) | NM_001164277 | Worldwide | 46% | 1 in 354 | 1 in 654 |
|
||||
| Glycogen storage disease type III (AGL) | NM_000642 | Faroese | 99% | 1 in 30 | 1 in 2900 |
|
||||
| Glycogen storage disease type III (AGL) | NM_000642 | North African Jewish | 99% | 1 in 37 | 1 in 3600 |
|
||||
| Glycogen storage disease type III (AGL) | NM_000642 | Worldwide | 85% | 1 in 159 | 1 in 1054 |
|
||||
| GM1 gangliosidosis and mucopolysaccharidosis type IVB (GLB1) | NM_000404 | Worldwide | 45% | 1 in 160 | 1 in 290 |
|
||||
| GRACILE syndrome (BCS1L) | NM_004328 | Finnish | 99% | 1 in 110 | 1 in 10,900 |
|
||||
| Guanidinoacetate methyltransferase deficiency (GAMT) | NM_000156 | Portuguese | 83% | 1 in 125 | 1 in 730 |
|
||||
| Guanidinoacetate methyltransferase deficiency (GAMT) | NM_000156 | Worldwide | 68% | N/A* | N/A |
|
||||
| Hereditary fructose Intolerance (ALDOB) | NM_000035 | Worldwide | 75% | 1 in 71 | 1 in 281 |
|
||||
| HMG-CoA lyase deficiency (HMGCL) | NM_000191 | Saudi Arabian | 86% | N/A* | N/A |
|
||||
| HMG-CoA lyase deficiency (HMGCL) | NM_000191 | Spanish/Portuguese | 85% | N/A* | N/A |
|
||||
| Holocarboxylase synthetase deficiency (HLCS) | NM_000411 | Worldwide | 66% | 1 in 158 | 1 in 463 |
|
||||
| Homocystinuria, CBS-related (CBS) | NM_000071 | United States | 65% | 1 in 227 | 1 in 647 |
|
||||
| Hypophosphatasia, autosomal recessive (ALPL) | NM_000478 | Japanese | 55% | N/A* | N/A |
|
||||
| Hypophosphatasia, autosomal recessive (ALPL) | NM_000478 | Mennonite | 99% | 1 in 25 | 1 in 2400 |
|
||||
| Joubert syndrome 2 (TMEM216) | NM_001173990 | Ashkenazi Jewish | 99% | 1 in 92 | 1 in 9100 |
|
||||
| Junctional epidermolysis bullosa, LAMA3-related (LAMA3) | NM_000227 | Pakistani | 99% | N/A* | N/A |
|
||||
| Junctional epidermolysis bullosa, LAMB3-related (LAMB3) | NM_000228 | Worldwide | 55% | 1 in 418 | 1 in 927 |
|
||||
| Junctional epidermolysis bullosa, LAMC2-related (LAMC2) | NM_005562 | Italian | 29% | 1 in 425 | 1 in 598 |
|
||||
| Krabbe disease (GALC) | NM_000153 | Caucasian | 60% | 1 in 158 | 1 in 393 |
|
||||
| Leigh syndrome, autosomal recessive (FOXRED1, NDUFAF2, NDUFS4, NDUFS7, NDUFV1, COX15, SURF1) | NM_017547, NM_174889, NM_002495, NM_024407, NM_007103, NM_004376, NM_003172 | Worldwide | 30% | 1 in 100 | 1 in 142 |
|
||||
| Leigh syndrome, French Canadian type (LRPPRC) | NM_133259 | French Canadian | 98% | 1 in 23 | 1 in 1100 |
|
||||
| Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHAD) (HADHA) | NM_000182 | Dutch | 87% | 1 in 158 | 1 in 1208 |
|
||||
| Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHAD) (HADHA) | NM_000182 | Worldwide | 71% | 1 in 138 | 1 in 473 |
|
||||
| Maple syrup urine disease type 1A (BCKDHA) | NM_000709 | Mennonite | 99% | 1 in 13 | 1 in 1200 |
|
||||
| Maple syrup urine disease type 1B (BCKDHB) | NM_183050 | Ashkenazi Jewish | 95% | 1 in 97 | 1 in 1921 |
|
||||
| Medium-chain acyl-CoA dehydrogenase deficiency (MCAD) (ACADM) | NM_000016 | United States | 79% | 1 in 63 | 1 in 296 |
|
||||
| Metachromatic leukodystrophy (ARSA) | NM_000487 | Caucasian | 56% | 1 in 141 | 1 in 319 |
|
||||
| Metachromatic leukodystrophy (ARSA) | NM_000487 | Japanese | 50% | 1 in 132 | 1 in 263 |
|
||||
| Methylmalonic acidemia, MMAA-related (MMAA) | NM_172250 | Caucasian | 80% | 1 in 300 | 1 in 1496 |
|
||||
| Methylmalonic acidemia, MMAB-related (MMAB) | NM_052845 | Caucasian | 70% | 1 in 435 | 1 in 1448 |
|
||||
| Methylmalonic acidemia, MUT-related (MUT) | NM_000255 | African American | 59% | 1 in 195 | 1 in 474 |
|
||||
| Methylmalonic acidemia, MUT-related (MUT) | NM_000255 | Hispanic | 63% | 1 in 195 | 1 in 525 |
|
||||
| Mitochondrial acetoacetyl-CoA thiolase deficiency (ACAT1) | NM_000019 | Vietnamese | 94% | N/A* | N/A |
|
||||
| Mitochondrial acetoacetyl-CoA thiolase deficiency (ACAT1) | NM_000019 | Worldwide | 65% | N/A* | N/A |
|
||||
| Mucolipidosis type II and III, GNPTAB-related (GNPTAB) | NM_024312 | French Canadian | 99% | 1 in 39 | 1 in 3800 |
|
||||
| Mucolipidosis type II and III, GNPTAB-related (GNPTAB) | NM_024312 | Worldwide | 79% | 1 in 152 | 1 in 720 |
|
||||
| Mucolipidosis type IV (MCOLN1) | NM_020533 | Ashkenazi Jewish | 96% | 1 in 89 | 1 in 2200 |
|
||||
| Mucopolysaccharidosis type I (IDUA) | NM_000203 | Caucasian | 60% | 1 in 158 | 1 in 393 |
|
||||
| Mucopolysaccharidosis type I (IDUA) | NM_000203 | Japanese | 42% | 1 in 158 | 1 in 271 |
|
||||
| Mucopolysaccharidosis type I (IDUA) | NM_000203 | Scandinavian | 79% | 1 in 158 | 1 in 748 |
|
||||
| Mucopolysaccharidosis type II (IDS) | NM_000202 | Worldwide | 44% | N/A** | N/A |
|
||||
| Mucopolysaccharidosis type IIIA (SGSH) | NM_000199 | Worldwide | 70% | 1 in 170 | 1 in 564 |
|
||||
| Mucopolysaccharidosis type IIIB (NAGLU) | NM_000263 | Dutch | 73% | 1 in 244 | 1 in 901 |
|
||||
| Mucopolysaccharidosis type IIIB (NAGLU) | NM_000263 | Worldwide | 42% | 1 in 220 | 1 in 379 |
|
||||
| Mucopolysaccharidosis type IIIC (HGSNAT) | NM_152419 | Worldwide | 67% | N/A* | N/A |
|
||||
| Mucopolysaccharidosis type IIID (GNS) | NM_002076 | Worldwide | 62% | N/A* | N/A |
|
||||
| Mucopolysaccharidosis type IVA (GALNS) | NM_000512 | General | 49% | 1 in 250 | 1 in 489 |
|
||||
| Mucopolysaccharidosis type VI (ARSB) | NM_000046 | Worldwide | 42% | 1 in 250 | 1 in 430 |
|
||||
| Mucopolysaccharidosis type VII (GUSB) | NM_000181 | Worldwide | 48% | N/A* | N/A |
|
||||
| Multiple sulphatase deficiency (SUMF1) | NM_182760 | Ashkenazi Jewish | N/A* | N/A | N/A |
|
||||
| Nemaline myopathy, NEB-related (NEB) | NM_001271208 | Ashkenazi Jewish | 95% | 1 in 168 | 1 in 3341 |
|
||||
| Nephrotic syndrome, NPHS1-related (NPHS1) | NM_004646 | Finnish | 94% | 1 in 45 | 1 in 734 |
|
||||
| Nephrotic syndrome, NPHS1-related (NPHS1) | NM_004646 | Maltese | 99% | 1 in 22 | 1 in 2100 |
|
||||
| Nephrotic syndrome, NPHS2-related (NPHS2) | NM_014625 | Worldwide | 60% | N/A* | N/A |
|
||||
| Neuronal ceroid-lipofuscinosis, CLN3-related (CLN3) | NM_001042432 | General | 85% | 1 in 230 | 1 in 1527 |
|
||||
| Neuronal ceroid-lipofuscinosis, CLN5-related (CLN5) | NM_006493 | Finnish | 99% | 1 in 115 | 1 in 11,400 |
|
||||
| Neuronal ceroid-lipofuscinosis, CLN8-related (CLN8) | NM_018941 | Finnish | 99% | 1 in 135 | 1 in 13,400 |
|
||||
| Neuronal ceroid-lipofuscinosis, PPT1-related (PPT1) | NM_000310 | Finnish | 98% | 1 in 67 | 1 in 3300 |
|
||||
| Neuronal ceroid-lipofuscinosis, PPT1-related (PPT1) | NM_000310 | General | 57% | 1 in 480 | 1 in 1114 |
|
||||
| Neuronal ceroid-lipofuscinosis, TPP1-related (TPP1) | NM_000391 | General | 53% | 1 in 250 | 1 in 530 |
|
||||
| Niemann-Pick disease type C, NPC1-related (NPC1) | NM_000271 | Worldwide | 31% | 1 in 183 | 1 in 265 |
|
||||
| Niemann-Pick disease types A and B (SMPD1) | NM_000543 | Ashkenazi Jewish | 97% | 1 in 116 | 1 in 3834 |
|
||||
| Niemann-Pick disease types A and B (SMPD1) | NM_000543 | Worldwide | 40% | 1 in 250 | 1 in 416 |
|
||||
| Niemann-Pick disease type C, NPC2-related (NPC2) | NM_006432 | Worldwide | 56% | 1 in 866 | 1 in 1966 |
|
||||
| Nijmegen breakage syndrome (NBN) | NM_002485 | Eastern European Slavic | 99% | 1 in 177 | 1 in 17,600 |
|
||||
| Ornithine transcarbamylase deficiency (OTC) | NM_000531 | Worldwide | 50% | N/A** | N/A |
|
||||
| Phenylalanine hydroxylase deficiency, includes phenylketonuria (PKU) (PAH) | NM_000277 | Caucasian | 57% | 1 in 50 | 1 in 114 |
|
||||
| Phenylalanine hydroxylase deficiency, includes phenylketonuria (PKU) (PAH) | NM_000277 | Irish | 69% | 1 in 33 | 1 in 104 |
|
||||
| Phenylalanine hydroxylase deficiency, includes phenylketonuria (PKU) (PAH) | NM_000277 | Turkish | 55% | 1 in 26 | 1 in 56 |
|
||||
| Phosphoglycerate dehydrogenase deficiency, PHGDH-related (PHGDH) | NM_006623 | Ashkenazi Jewish | N/A* | N/A | N/A |
|
||||
| Polycystic kidney disease, autosomal recessive (PKHD1) | NM_138694 | Finnish | 79% | 1 in 70 | 1 in 329 |
|
||||
| Polycystic kidney disease, autosomal recessive (PKHD1) | NM_138694 | Worldwide | 59% | 1 in 70 | 1 in 169 |
|
||||
| Pompe disease (GAA) | NM_000152 | African American | 43% | 1 in 60 | 1 in 104 |
|
||||
| Pompe disease (GAA) | NM_000152 | Chinese | 80% | 1 in 112 | 1 in 556 |
|
||||
| Pompe disease (GAA) | NM_000152 | Dutch | 64% | 1 in 100 | 1 in 276 |
|
||||
| Primary hyperoxaluria type 1 (AGXT) | NM_000030 | Worldwide | 46% | 1 in 289 | 1 in 534 |
|
||||
| Primary hyperoxaluria type 2 (GRHPR) | NM_012203 | Asian | 50% | N/A* | N/A |
|
||||
| Primary hyperoxaluria type 2 (GRHPR) | NM_012203 | Caucasian | 58% | N/A* | N/A |
|
||||
| Propionic acidemia, PCCA-related (PCCA) | NM_000282 | Japanese | 70% | 1 in 65 | 1 in 214 |
|
||||
| Propionic acidemia, PCCB-related (PCCB) | NM_000532 | Caucasian | 32% | 1 in 112 | 1 in 164 |
|
||||
| Propionic acidemia, PCCB-related (PCCB) | NM_000532 | Japanese | 77% | 1 in 65 | 1 in 279 |
|
||||
| Propionic acidemia, PCCB-related (PCCB) | NM_000532 | Latin American | 91% | 1 in 112 | 1 in 1234 |
|
||||
| Propionic acidemia, PCCB-related (PCCB) | NM_000532 | Spanish | 68% | 1 in 112 | 1 in 338 |
|
||||
| Pyruvate dehydrogenase deficiency, PDHA1-related (PDHA1) | NM_000284 | Worldwide | 40% | N/A** | N/A |
|
||||
| Retinitis pigmentosa 59 (DHDDS) | NM_024887 | Ashkenazi Jewish | 95% | 1 in 322 | 1 in 6420 |
|
||||
| Rhizomelic chondrodysplasia punctata type 1 (PEX7) | NM_000288 | Worldwide | 72% | 1 in 158 | 1 in 561 |
|
||||
| Salla disease (SLC17A5) | NM_012434 | Finnish | 96% | 1 in 200 | 1 in 4976 |
|
||||
| Sandhoff disease (HEXB) | NM_000521 | Italian | 75% | N/A* | N/A |
|
||||
| Sialidosis (NEU1) | NM_000434 | Chinese | 89% | N/A* | N/A |
|
||||
| Sialidosis (NEU1) | NM_000434 | Worldwide | 49% | N/A* | N/A |
|
||||
| Sjogren-Larsson syndrome (ALDH3A2) | NM_000382 | Swedish | 87% | 1 in 200 | 1 in 1531 |
|
||||
| Smith-Lemli-Opitz syndrome (DHCR7) | NM_001360 | Worldwide | 75% | 1 in 71 | 1 in 281 |
|
||||
| Sulfate transporter-related osteochondrodysplasias (SLC26A2) | NM_000112 | Finnish | 96% | 1 in 50 | 1 in 1226 |
|
||||
| Sulfate transporter-related osteochondrodysplasias (SLC26A2) | NM_000112 | General | 70% | 1 in 158 | 1 in 524 |
|
||||
| Systemic primary carnitine deficiency (SLC22A5) | NM_003060 | Worldwide | 43% | 1 in 130 | 1 in 227 |
|
||||
| Tay-Sachs disease (HEXA) | NM_000520 | Ashkenazi Jewish | 96%*** | 1 in 27*** | 1 in 650 |
|
||||
| Tay-Sachs disease (HEXA) | NM_000520 | US French Canadian | 47%*** | 1 in 73*** | 1 in 136 |
|
||||
| Tay-Sachs disease (HEXA) | NM_000520 | Worldwide | 46%*** | 1 in 300*** | 1 in 554 |
|
||||
| Tyrosinemia type 1 (FAH) | NM_000137 | Ashkenazi Jewish | 99% | 1 in 158 | 1 in 15,700 |
|
||||
| Tyrosinemia type 1 (FAH) | NM_000137 | Finnish | 95% | 1 in 122 | 1 in 2421 |
|
||||
| Tyrosinemia type 1 (FAH) | NM_000137 | French Canadian | 95% | 1 in 56 | 1 in 1100 |
|
||||
| Tyrosinemia type 1 (FAH) | NM_000137 | Worldwide | 72% | 1 in 158 | 1 in 562 |
|
||||
| Usher syndrome type IF (PCDH15) | NM_033056 | Ashkenazi Jewish | 75% | 1 in 147 | 1 in 585 |
|
||||
| Usher syndrome type IIIA (CLRN1) | NM_174878 | Ashkenazi Jewish | 98% | 1 in 120 | 1 in 5951 |
|
||||
| Usher syndrome type IIIA (CLRN1) | NM_174878 | Finnish | 98% | 1 in 134 | 1 in 6650 |
|
||||
| Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD) (ACADVL) | NM_000018 | Worldwide | 34% | 1 in 222 | 1 in 336 |
|
||||
| Walker-Warburg syndrome, FKTN-related (FKTN) | NM_001079802 | Ashkenazi Jewish | 99% | 1 in 79 | 1 in 7800 |
|
||||
| Wilson disease (ATP7B) | NM_000053 | Asian | 39% | 1 in 50 | 1 in 81 |
|
||||
| Wilson disease (ATP7B) | NM_000053 | Caucasian | 55% | 1 in 90 | 1 in 199 |
|
||||
| Xeroderma pigmentosum, ERCC5-related (ERCC5) | NM_000123 | Worldwide | 68% | N/A* | N/A |
|
||||
| Xeroderma pigmentosum, XPA-related (XPA) | NM_000380 | Worldwide | 91% | N/A* | N/A |
|
||||
| Xeroderma pigmentosum, XPA-related (XPA) | NM_000380 | Japanese | 90% | 1 in 113 | 1 in 1120 |
|
||||
| Xeroderma pigmentosum, XPC-related (XPC) | NM_004628 | Tunisian | 99% | 1 in 50 | 1 in 4900 |
|
||||
| Xeroderma pigmentosum, XPC-related (XPC) | NM_004628 | Worldwide | 76% | N/A* | N/A |
|
||||
| X-linked severe combined Immunodeficiency (SCID) (IL2RG) | NM_000206 | Worldwide | 68% | N/A** | N/A |
|
||||
| Zellweger spectrum disorder, PEX10-related (PEX10) | NM_153818 | Worldwide | 17% | 1 in 646 | 1 in 778 |
|
||||
| Zellweger spectrum disorder, PEX12-related (PEX12) | NM_000286 | Worldwide | 21 | 1 in 373 | 1 in 472 |
|
||||
| Zellweger spectrum disorder, PEX1-related (PEX1) | NM_000466 | Worldwide | 67% | 1 in 134 | 1 in 404 |
|
||||
| Zellweger spectrum disorder, PEX26-related (PEX26) | NM_017929 | Worldwide | 27% | 1 in 646 | 1 in 885 |
|
||||
| Zellweger spectrum disorder, PEX2-related (PEX2) | NM_000318 | Ashkenazi Jewish | N/A* | 1 in 123 | N/A |
|
||||
| Zellweger spectrum disorder, PEX6-related (PEX6) | NM_000287 | Worldwide | 23% | 1 in 280 | 1 in 363 |
|
||||
|
||||
\* Not available: insufficient published data
|
||||
\*\* Not available: for this X-linked disease carrier risk is different for males and females and cannot be obtained from observed incidence of the disorder as some female carriers are symptomatic
|
||||
\*\*\* Excludes pseudodeficiency alleles
|
||||
\*\*\*\* The carrier frequency in healthy Ashkenazi Jewish individuals has been reported to be as high as 1 in 5; however, the carrier frequency of 1 in 81 is based on the observed incidence of disorder
|
||||
|
||||
**Disclaimer:** This test was developed and its performance characteristics determined by Esoterix Genetic Laboratories, LLC. It has not been cleared or approved by the Food and Drug Administration.
|
||||
|
||||
Integrated Genetics is a business unit of Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of Laboratory Corporation of America Holdings. Inheritest(R) is a registered service mark of Laboratory Corporation of America Holdings.
|
||||
|
||||
**Director Review:** JENNIFER REINER PHD, FACMG
|
||||
|
||||
**Ordering provider:** Candice B. Tilles, MD
|
||||
**Collection date:** Sep 15, 2021 2:09 PM
|
||||
**Specimens:** Blood (Antecubital, Left)
|
||||
**Result date:** Oct 01, 2021 9:06 AM
|
||||
**Result status:** Final
|
||||
**Resulting lab:** REFERENCE LAB LABCORP - BKR, 13112 Evening Creek Drive South, San Diego CA 92128, 858-668-3700
|
||||
**Lab director:** Jenny Galloway, MD
|
||||
|
||||
---
|
||||
|
||||
## PAP, REFLEX HIGH RISK HPV IF ASCUS/ACG
|
||||
|
||||
**Collected on:** Oct 20, 2021
|
||||
|
||||
### Provider Message
|
||||
|
||||
**Candice B. Tilles, MD** - 10/25/2021, 8:41 AM
|
||||
|
||||
> Hi Erica,
|
||||
>
|
||||
> Your Pap smear was normal. Please follow up for your next pap smear in one year. Hope all is well!
|
||||
>
|
||||
> Dr. Tilles
|
||||
|
||||
### Result Information
|
||||
|
||||
| Field | Value |
|
||||
|-------|-------|
|
||||
| Status | Final result (10/21/2021 4:06 PM PDT) |
|
||||
| Priority | Routine |
|
||||
| Source | Cervix |
|
||||
| Order | 1100525376 |
|
||||
| Dx | Well woman exam with routine gynecolo... |
|
||||
| Next appt | 11/03/2026 at 08:30 AM in Primary Care (Elizabeth Spence, DO) |
|
||||
|
||||
| Component | Comment |
|
||||
|-----------|---------|
|
||||
| Specimen adequacy | Satisfactory for evaluation. Endocervical and/or squamous metaplastic cells (endocervical component) are present. |
|
||||
| DIAGNOSIS | NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY. |
|
||||
| Clinician Provided ICD | Z01.419 |
|
||||
| Performed by | Daniel Spikings, Cytotechnologist (ASCP) |
|
||||
| Microscopic description | . |
|
||||
| Note | The Pap smear is a screening test designed to aid in the detection of premalignant and malignant conditions of the uterine cervix. It is not a diagnostic procedure and should not be used as the sole means of detecting cervical cancer. Both false-positive and false-negative reports do occur. |
|
||||
| Methodology | This liquid based ThinPrep(R) pap test was screened with the use of an image guided system. |
|
||||
| Pathology Comment 1 | The HPV DNA reflex criteria were not met with this specimen result therefore, no HPV testing was performed. |
|
||||
|
||||
**Narrative:**
|
||||
Performed at: 01 - LabCorp Monrovia, 605 East Huntington Drive Ste 209, Monrovia, CA 910166353
|
||||
Lab Director: Mona Yong MD, Phone: 6264713500
|
||||
Specimen Comment: Source...........Cervix
|
||||
Specimen Comment: Dates / Results....No
|
||||
Specimen Comment: No. of containers..01 ThinPrep Vial
|
||||
|
||||
**Specimen Collected:** 10/20/2021 2:25 PM PDT
|
||||
**Last Resulted:** 10/21/2021 4:06 PM PDT
|
||||
|
||||
### Health Maintenance
|
||||
|
||||
| Topic | Next Due |
|
||||
|-------|----------|
|
||||
| Cervical Cancer Screening (Pap/HPV) (Every 5 Years) | 9/12/2030 |
|
||||
|
||||
**Authorizing Provider:** Candice Bianca Tilles, MD
|
||||
- Phone: 310-829-7878
|
||||
- Fax: 310-453-5586
|
||||
|
||||
**Reviewer:** Candice Bianca Tilles, MD on 10/25/2021 8:41 AM
|
||||
|
||||
---
|
||||
|
||||
## PROLACTIN
|
||||
|
||||
**Collected on:** Sep 15, 2021 2:09 PM
|
||||
|
||||
**Performed at:** 01 - LabCorp San Diego, 13112 Evening Creek Dr So Ste 200, San Diego, CA 921284108
|
||||
**Lab Director:** Jenny Galloway MD, Phone: 8586683700
|
||||
|
||||
| Test | Value | Unit | Normal Range |
|
||||
|------|-------|------|--------------|
|
||||
| Prolactin | 17 | ng/mL | 4.8 - 23.3 |
|
||||
|
||||
**Ordering provider:** Candice B. Tilles, MD
|
||||
**Collection date:** Sep 15, 2021 2:09 PM
|
||||
**Specimens:** Blood (Arm, Left)
|
||||
**Result date:** Sep 16, 2021 8:06 AM
|
||||
**Result status:** Final
|
||||
**Resulting lab:** REFERENCE LAB LABCORP - BKR, 13112 Evening Creek Drive South, San Diego CA 92128, 858-668-3700
|
||||
**Lab director:** Jenny Galloway, MD
|
||||
|
||||
---
|
||||
|
||||
## RUBELLA ANTIBODY, IGG
|
||||
|
||||
**Collected on:** Sep 15, 2021 2:09 PM
|
||||
|
||||
**Performed at:** 01 - LabCorp San Diego, 13112 Evening Creek Dr So Ste 200, San Diego, CA 921284108
|
||||
**Lab Director:** Jenny Galloway MD, Phone: 8586683700
|
||||
|
||||
| Test | Value | Unit | Normal Value |
|
||||
|------|-------|------|-------------|
|
||||
| Rubella IgG Ab | 1.36 | index | Immune >0.99 |
|
||||
|
||||
| Interpretation | Index Range |
|
||||
|----------------|-------------|
|
||||
| Non-immune | <0.90 |
|
||||
| Equivocal | 0.90 - 0.99 |
|
||||
| Immune | >0.99 |
|
||||
|
||||
**Ordering provider:** Candice B. Tilles, MD
|
||||
**Collection date:** Sep 15, 2021 2:09 PM
|
||||
**Specimens:** Blood (Arm, Left)
|
||||
**Result date:** Sep 21, 2021 3:05 PM
|
||||
**Result status:** Final
|
||||
**Resulting lab:** REFERENCE LAB LABCORP - BKR, 13112 Evening Creek Drive South, San Diego CA 92128, 858-668-3700
|
||||
**Lab director:** Jenny Galloway, MD
|
||||
|
||||
---
|
||||
|
||||
## RUBEOLA ANTIBODY, IGG
|
||||
|
||||
**Collected on:** Sep 15, 2021 2:09 PM
|
||||
|
||||
**Performed at:** 01 - LabCorp San Diego, 13112 Evening Creek Dr So Ste 200, San Diego, CA 921284108
|
||||
**Lab Director:** Jenny Galloway MD, Phone: 8586683700
|
||||
|
||||
| Test | Value | Unit | Normal Value |
|
||||
|------|-------|------|-------------|
|
||||
| Rubeola IgG (REF) | 150.0 | AU/mL | Immune >16.4 |
|
||||
|
||||
| Interpretation | AU/mL Range |
|
||||
|----------------|-------------|
|
||||
| Negative | <13.5 |
|
||||
| Equivocal | 13.5 - 16.4 |
|
||||
| Positive | >16.4 |
|
||||
|
||||
Presence of antibodies to Rubeola is presumptive evidence of immunity except when acute infection is suspected.
|
||||
|
||||
**Ordering provider:** Candice B. Tilles, MD
|
||||
**Collection date:** Sep 15, 2021 2:09 PM
|
||||
**Specimens:** Blood (Arm, Left)
|
||||
**Result date:** Sep 16, 2021 8:06 AM
|
||||
**Result status:** Final
|
||||
**Resulting lab:** REFERENCE LAB LABCORP - BKR, 13112 Evening Creek Drive South, San Diego CA 92128, 858-668-3700
|
||||
**Lab director:** Jenny Galloway, MD
|
||||
|
||||
---
|
||||
|
||||
## Thyroid Stimulating Hormone
|
||||
|
||||
**Collected on:** Sep 15, 2021 2:09 PM
|
||||
|
||||
| Test | Value | Unit | Normal Range |
|
||||
|------|-------|------|--------------|
|
||||
| TSH | 3.03 | uIU/mL | 0.50 - 5.80 |
|
||||
|
||||
**Ordering provider:** Candice B. Tilles, MD
|
||||
**Collection date:** Sep 15, 2021 2:09 PM
|
||||
**Specimens:** Blood (Arm, Left)
|
||||
**Result date:** Sep 15, 2021 7:50 PM
|
||||
**Result status:** Final
|
||||
**Resulting lab:** CA PJNF WOMENS HEALTH SM LAB (CLIA 05D0550213), 2001 SANTA MONICA BLVD STE 970W, SANTA MONICA CA 90404-2199, 310-829-7878
|
||||
**Lab director:** Jon S. Matsunaga, MD
|
||||
**CLIA #:** 05D0550213
|
||||
|
||||
---
|
||||
|
||||
## US ECHOGRAPHY TRANSVAGINAL
|
||||
|
||||
### Results
|
||||
|
||||
**US Non-Ob Transvaginal [IMG547]** (Accession 23201068PRV) (Order 1080882493)
|
||||
|
||||
**9/15/2021 4:44 PM - Candice Bianca Tilles, MD**
|
||||
|
||||
### Narrative & Impression
|
||||
|
||||
**Patient Name:** Xuewei Jiang
|
||||
**Age:** 28 y.o.
|
||||
**DOB:** 3/13/1993
|
||||
**Medical Record Number:** 20018501333
|
||||
**Date of Service:** 9/15/2021
|
||||
|
||||
**Ultrasound Name:** GYN Ultrasound
|
||||
|
||||
**Comments:**
|
||||
- UT and CVX WNL
|
||||
- EMS meas 4.8 MM
|
||||
- Bilat OVS and ADX WNL
|
||||
|
||||
**Electronically Signed by:** Gabrielle S Decker, Ultrasound Tech, 9/15/2021 12:57 PM PDT
|
||||
|
||||
**Impression:** Please see technician's comments.
|
||||
|
||||
**Electronically Signed by:** Candice B. Tilles, MD, 9/15/2021 4:44 PM PDT
|
||||
|
||||
**Result History:** US Non-Ob Transvaginal (Order #1080882493) on 9/15/2021
|
||||
|
||||
**Performing Facility:** SJPP WOMENS HEALTH SANTA MONICA, 2001 SANTA MONICA BLVD STE 970W, SANTA MONICA, California 90404-2199, 310-829-7878
|
||||
|
||||
**Reviewed by:** Candice Bianca Tilles, MD - 9/17/2021 5:23 PM
|
||||
|
||||
---
|
||||
|
||||
## Varicella-Zoster Antibody, IgG
|
||||
|
||||
**Collected on:** Sep 15, 2021 2:09 PM
|
||||
|
||||
**Performed at:** 01 - LabCorp San Diego, 13112 Evening Creek Dr So Ste 200, San Diego, CA 921284108
|
||||
**Lab Director:** Jenny Galloway MD, Phone: 8586683700
|
||||
|
||||
| Test | Value | Unit | Normal Value |
|
||||
|------|-------|------|-------------|
|
||||
| Varicella zoster Ab IgG | 513 | index | Immune >165 |
|
||||
|
||||
| Interpretation | Index Range |
|
||||
|----------------|-------------|
|
||||
| Negative | <135 |
|
||||
| Equivocal | 135 - 165 |
|
||||
| Positive | >165 |
|
||||
|
||||
A positive result generally indicates exposure to the pathogen or administration of specific immunoglobulins, but it is not indication of active infection or stage of disease.
|
||||
|
||||
**Ordering provider:** Candice B. Tilles, MD
|
||||
**Collection date:** Sep 15, 2021 2:09 PM
|
||||
**Specimens:** Blood (Arm, Left)
|
||||
**Result date:** Sep 16, 2021 8:06 AM
|
||||
**Result status:** Final
|
||||
**Resulting lab:** REFERENCE LAB LABCORP - BKR, 13112 Evening Creek Drive South, San Diego CA 92128, 858-668-3700
|
||||
**Lab director:** Jenny Galloway, MD
|
||||
Reference in New Issue
Block a user